Table 4.
Characteristics of radiotherapy combined with chemotherapy and chemotherapy alone groups in the before and after PSM cohorts.
| Before PSM cohort (n=255) | After PSM cohort (n=180) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Total(n=255) | CT without RT(n=134) | RT with CT(n=121) | p | Total(n=180) | CT without RT(n=90) | RT with CT(n=90) | p | SMD |
| Age | 0.932 | 0.696 | 0.093 | ||||||
| Years (median[IQR]) | 255 | 73.0[66.0,79.0] | 73.0[64.0,82.0] | 180 | 75.0[66.0,79.0] | 73.0[64.0,81.8] | |||
| Race (%) | 0.269 | 0.529 | 0.169 | ||||||
| Black | 17 | 11(8.2) | 6 (5.0) | 15 | 9(10.0) | 6(6.7) | |||
| White | 231 | 121(90.3) | 110 (90.9) | 159 | 79(87.8) | 8088.9) | |||
| Others | 7 | 2(1.5) | 5 (4.1) | 6 | 2(2.2) | 4 (4.4) | |||
| Sex (%) | 0.428 | 0.852 | 0.056 | ||||||
| Male | 200 | 102(76.1) | 98 (81.0) | 144 | 71(78.9) | 73 (81.1) | |||
| Female | 55 | 32(23.9) | 23 (19.0) | 36 | 19(21.1) | 17 (18.9) | |||
| T stage (%) | 0.624 | 0.537 | 0.221 | ||||||
| Tis | 1 | 0 (0.0) | 1(0.8) | 0 | 0 (0.0) | 0 (0.0) | |||
| T1 | 52 | 25 (18.7) | 27 (22.3) | 37 | 15(16.7) | 22 (24.4) | |||
| T2 | 159 | 83 (61.9) | 76(62.8) | 112 | 57 (63.3) | 55(61.1) | |||
| T3 | 20 | 12(9.0) | 8 (6.6) | 14 | 8(8.9) | 6(6.7) | |||
| T4 | 23 | 14 (10.4) | 9 (7.4) | 17 | 10 (11.1) | 7(7.8) | |||
| N stage(%) | 0.443 | 0.469 | 0.135 | ||||||
| N0 | 198 | 101(75.4) | 97(80.2) | 151 | 68(75.6) | 73(81.1) | |||
| N1 | 57 | 33(24.6) | 24(19.8) | 39 | 22(24.4) | 17(18.9) | |||
| Bone metastases(%) | 0.372 | 1.000 | 0.035 | ||||||
| Yes | 29 | 18(13.4) | 11(9.1) | 21 | 11(12.2) | 10(11.1) | |||
| No | 226 | 116(86.6) | 110(90.9) | 159 | 79(87.8) | 80(88.9) | |||
| Liver metastases(%) | 0.003* | 1.000 | <0.001 | ||||||
| Yes | 40 | 30(22.4) | 10(8.3) | 16 | 8(8.9) | 8(8.9) | |||
| No | 215 | 104(77.6) | 111(91.7) | 164 | 82(91.1) | 82(91.1) | |||
| Lung metastases(%) | 0.128 | 0.613 | 0.151 | ||||||
| Yes | 13 | 10(7.5) | 3(2.5) | 4 | 1(1.1) | 3(3.3) | |||
| No | 242 | 124(92.5) | 118(97.5) | 176 | 89(98.9) | 87(96.7) | |||
| Brain metastases (%) | 0.544 | 0.244 | 0.263 | ||||||
| Yes | 4 | 1(0.7) | 3(2.5) | 3 | 0(0.0) | 3(3.3) | |||
| No | 251 | 133(99.3) | 118(97.5) | 177 | 90(100.0) | 87(96.7) | |||
| Tumor size | 0.009* | 1.000 | <0.001 | ||||||
| Centimetre (median[IQR]) | 255 | 8.0[4.0,11.0] | 5.0[3.0,11.0] | 180 | 7.0[4.0,11.0] | 7.0[4.0,11.0] | |||
PSM, propensity score matching; IQR, interquartile range; RT with CT, radiotherapy combined with chemotherapy; CT without RT, chemotherapy without radiotherapy; T stage, tumour stage; N stage, node stage; p, P value; SMD, STD Mean Difference.